The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
November 23rd 2024
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
November 18th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Allen Anderson: Specialized Centers Provided Additional Care Benefitting Patients
Patients diagnosed with heart failure face a variety of challenges with the condition over the course of their lifetime. As a result specialized centers can help provide the best care and help overall quality of life.
Allen Anderson from Northwestern Medicine: Treatment of Heart Failure Still Poses Challenges in Care
The diagnosis of heart failure is a common problem cardiologists face on a daily basis both in the hospital and outpatient settings. Finding the best treatments to help their quality life remains an issue being addressed across cardiology.
Andrew Hoel: Keeping Up with the Latest Techniques in Vascular Surgery
There are constantly new innovations being developed in vascular surgery, particularly when it comes to the treatment of aneurysms and Northwestern University is one place where that work is being spearheaded.
Andrew Hoel from Northwestern Medicine: Vascular Surgeons Face Many Challenges in the Operating Room
Vascular surgery can mean operating on many parts of the body and as a result can mean surgeons face unique challenges with each procedure even as technology rapidly improves the field.
Sonal Bhatia from Pfizer: Eliquis Continues to Show Positive Results in Real World Trials
It has been several years since Eliquis was approved as an oral anticoagulant but still more research is being done to show its benefits in helping patients with non-valvular atrial fibrillation.
Jennifer Robinson: Improving Accessibility to PCSK9 Inhibitors One Year Later
It was just one year ago when doctors were excited about being able to offer PCSK9 inhibitors to patients in the hopes of helping them lower their cholesterol. Since that time one considerable challenge they have faced is overcoming the cost of this new class of medication.
Piotr Slomka from Cedars-Sinai: Can Machines Replace Humans in Test Interpretation?
Across the spectrum of medicine machines are being trained to play a larger role in the diagnosis and treatment process. A recent study looked at whether machines are better at predicting the future for a patient and their overall care.
Experts Debunk Myths Surrounding Testosterone Deficiency and Treatment
In recent years, there have been questions raised about the true dangers of testosterone deficiency (TD) and the efficacy and side effects of testosterone therapy, particularly as they pertain to patients who are at risk for cardiovascular disease and prostate cancer.
High Doses of Imodium Cause Serious Heart Problems, FDA Warns
Over-the-counter diarrhea drug loperamide (Imodium/Johnson & Johnson Consumer Inc.) has recently been in the news because opioid abusers have been using it to self-treat symptoms of opioid withdrawal. Others abuse it for its euphoric properties.
Metabolic Surgery is Now a Recommended Treatment for Obese Patients with Type 2 Diabetes
New consensus guidelines for the treatment of type 2 diabetes mellitus (T2DM) recommend, for the first time, that metabolic surgery be recommended or considered as an intervention for many obese patients.
Many Women and Elderly Patients Receive Inadequate Treatment for AFib-Related Stroke Prevention
Study results show that women with atrial fibrillation are less likely to receive recommended thromboprophylaxis medications than men, and patients age 85 and older are often treated with aspirin as the sole antithrombotic agent.